Cardinal Health's Q4 Earnings Hit By Inflationary Impacts, Supply Chain Constraints; Lowers FY22 Outlook

Cardinal Health CAH has reported Q2 FY22 adjusted EPS of $1.27, down 27% Y/Y, beating the Street estimate of $1.23.

  • Earnings declined primarily due to inflationary impacts and global supply chain constraints in the Medical segment.
  • Q2 sales increased 9% Y/Y to $45.5 billion, missing the consensus estimate of $45.57 billion.
  • Related: Cardinal Health Expects Inflationary Impact, Supply Chain Constraints To Hit Volumes In FY22.
  • The pharmaceutical segment increased 11% to $41.4 billion, driven primarily by branded pharmaceutical sales growth from large Pharmaceutical Distribution and Specialty customers.
  • The medical segment sales decreased 5% to $4.1 billion, primarily due to Cordis's divestiture.
  • Outlook: For FY22, Cardinal Health revised adjusted EPS guidance to $5.15 - $5.50, down from the previous guidance of $5.60 - $5.90, compared to the consensus of $5.37.
  • The guidance reflects the previously announced additional $150 million - $175 million impacts from increased inflation and global supply chain constraints and a lower-than-expected offset from pricing actions. 
  • The Company has updated the Medical segment profit outlook of 30 - 45% decline, from mid-single to low-double-digit percentage decline.
  • Price Action: CAH shares are down 1.51% at $50.82 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!